Value of Current Chemotherapy and Surgery in Advanced and Metastatic Bladder Cancer

Marco Racioppi, Emilio Sacco, Pierfrancesco Bassi, Daniele D'Agostino, Angelo Totaro, Francesco Pinto, Alessandro D'Addessi, Francesco Marangi, Giuseppe Palermo

Risultato della ricerca: Contributo in rivistaArticolo in rivista

60 Citazioni (Scopus)

Abstract

The aim of the present paper was to review findings from the most relevant studies and to evaluate the value of current chemotherapy and surgery in advanced unresectable and metastatic bladder cancer. Studies were identified by searching the MEDLINE® and PubMed® databases up to 2011 using both medical subject heading (Mesh) and a free text strategy with the name of the known individual chemotherapeutic drug and the following key words: 'muscle-invasive bladder cancer', 'chemotherapeutics agents', and 'surgery in advanced bladder cancer'. At the end of our literature research we selected 141 articles complying with the aim of the review. The results showed that it has been many years since the MVAC (methotrexate, vinblastine, adriamycin, cisplatin) regimen was first developed. The use of cisplatin-based combination chemotherapy is associated with significant toxicity and produces long-term survival in only approximately 15-20% of patients. Gemcitabine + cisplatin represents the gold standard in the treatment of metastatic bladder cancer. In conclusion, the optimal approach in the management of advanced urothelial cancer continues to evolve. Further progress relies on the expansion of research into tumor biology and an understanding of the underlying molecular 'fingerprints' that can be used to enhance diagnostic and therapeutic strategies. Cisplatin-based therapy has had the best track record thus far
Lingua originaleEnglish
pagine (da-a)249-258
Numero di pagine10
RivistaUrologia Internationalis
Volume88
DOI
Stato di pubblicazionePubblicato - 2012

Keywords

  • Bladder cancer
  • Chemotherapy

Fingerprint Entra nei temi di ricerca di 'Value of Current Chemotherapy and Surgery in Advanced and Metastatic Bladder Cancer'. Insieme formano una fingerprint unica.

Cita questo